94078-20-3

Basic information

• Product Name: 5-(2-METHOXY-PHENYL)-FURAN-2-CARBALDEHYDE
• Synonyms: 5-(2-METHOXY-PHENYL)-FURAN-2-CARBALDEHYDE;5-(2-METHOXYPHENYL)-2-FURALDEHYDE;AKOS BAR-0561
• CAS NO: 94078-20-3
• Molecular Formula: C₁₂H₁₀O₃
• Molecular Weight: 202.21
• Mol File: 94078-20-3.mol
• Article Data: 14

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-(2-METHOXY-PHENYL)-FURAN-2-CARBALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(2-METHOXY-PHENYL)-FURAN-2-CARBALDEHYDE(94078-20-3)
• EPA Substance Registry System: 5-(2-METHOXY-PHENYL)-FURAN-2-CARBALDEHYDE(94078-20-3)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 94078-20-3(Hazardous Substances Data)

Upstream product

• 98-01-1 furfural 
• 3425-23-8 2-methoxybenzenediazonium chloride 
• 1899-24-7 5-bromo-2-furancarboxaldehyde 
• 5720-06-9 2-Methoxyphenylboronic acid 
• 27329-70-0 5-formylfurane-2-boronic acid 
• 529-28-2 4-iodoanisol 
• 578-57-4 2-bromoanisole 
• 2689-65-8 5-iodofuran-2-carbaldehyde 
• 100-66-3 methoxybenzene 

Downstream Products

• 1138343-18-6 2-(2-methoxyphenyl)-4H-furo[3,2-b]pyrrole-5-carboxylic acid ethyl ester 
• 1243598-62-0 1,2-bis[5-(2-methoxyphenyl)furan-2-yl]ethane-1,2-dione 
• 1339917-58-6 (Z)-3-ethyl-5-[5-(2-methoxyphenyl)furan-2-ylmethylene]oxazolidine-2,4-dithione 

Relevant articles and documents

TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE

The invention provides a variety of compounds having the structure of Formula I and uses of such compounds for treatment of various indications, including cancer as well as methods of treatment involving such compounds are also provided. The uses of the compounds may specifically include: bladder cancer, cholangiocarcinoma; colorectal cancer; diffuse large B-cell lymphoma (DLBC); liver cancer; ovarian cancer; thymoma; thyroid cancer; clear cell renal cell carcinoma (CCRCC); chromophobe renal cell carcinoma (ChRCC); prostate cancer; breast cancer; uterine cancer; pancreatic cancer; cervical cancer; uveal melanoma; acute myeloid leukemia (AML); head and neck cancer; small cell lung cancer (SCLC); lung adenocarcinoma sarcoma; mesothelioma; adenoid cystic carcinoma (ACC), sarcoma; testicular germ cell cancer; uterine cancer; pheochromocytoma and paraganglioma (PCPG); melanoma; glioma; glioblastoma multiforme; T-cell Acute Lymphoblastic Leukemia; T-cell Lympohoma, medulloblastoma; and neuroblastoma.

Identification of a small molecule inhibitor that stalls splicing at an early step of spliceosome activation

Small molecule inhibitors of pre-mRNA splicing are important tools for identifying new spliceosome assembly intermediates, allowing a finer dissection of spliceosome dynamics and function. Here, we identified a small molecule that inhibits human pre-mRNA splicing at an intermediate stage during conversion of pre-catalytic spliceosomal B complexes into activated Bact complexes. Characterization of the stalled complexes (designated B028) revealed that U4/U6 snRNP proteins are released during activation before the U6 Lsm and B-specific proteins, and before recruitment and/or stable incorporation of Prp19/CDC5L complex and other Bact complex proteins. The U2/U6 RNA network in B028 complexes differs from that of the Bact complex, consistent with the idea that the catalytic RNA core forms stepwise during the B to Bact transition and is likely stabilized by the Prp19/CDC5L complex and related proteins. Taken together, our data provide new insights into the RNP rearrangements and extensive exchange of proteins that occurs during spliceosome activation.

Synthesis and evaluation of compounds that induce readthrough of premature termination codons

A structure-activity relationship (SAR) study was carried out to identify novel, small molecular weight compounds which induce readthrough of premature termination codons. In particular, analogs of RTC13, 1, were evaluated. In addition, hypothesizing that these compounds exhibit their activity by binding to the ribosome, we prepared the hybrid analogs 13 containing pyrimidine bases and these also showed good readthrough activity.